Skip to main content

Cabaletta Bio, Inc.

corporate_fare Company Profile

Cabaletta Bio, Inc.

CABA·NASDAQ·Life Sciences·CIK 0001759138

Cabaletta Bio, Inc. is a late clinical-stage biotechnology company that discovers and develops engineered T cell therapies for autoimmune diseases. The company's proprietary CABA®, or Cabaletta Approach to B cell Ablation platform, utilizes the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) approach to potentially reset the immune system. This platform aims to enable complete and durable responses for a broad range of autoimmune diseases and has potential applicability across dozens of identified, evaluated, and prioritized autoimmune diseases. The company's lead product candidate within the CARTA strategy is Resecabtagene autoleucel, or rese-cel (formerly CABA-201). Rese-cel is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat a broad range of autoimmune diseases. It is engineered to achieve transient and deep depletion of all B cells following a single, weight-based infusion of T cells. This process allows for the deep elimination of all disease-contributing B cells, followed by repopulation with healthy transitional, naïve B cells, potentially resetting the immune system and leading to clinical responses without chronic therapy. The efficacy and safety of rese-cel were reviewed in a February 2026 Nature Biotechnology publication. In December 2025, the company initiated a registrational trial for rese-cel in patients with dermatomyositis or anti-synthetase syndrome.

Cabaletta Bio, Inc. (NASDAQ:CABA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for CABA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-08, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for CABA spans 10-Q, 8-K, DEFA14A, 424B5.

Recent high-impact activity:

  • Rese-cel Holds Immunomodulator-Free Responses at One Year Across Three Autoimmune Diseases
  • Cabaletta Bio 10-Q: Going-Concern Warning Lifted as Cash Reaches $299.4M
  • Cabaletta Extends Cash Runway Into 1Q28 With $299.4M, Starts Second Registrational Study
  • Cabaletta Bio Secures $128.2M from Warrant Exercises, Addressing Going Concern
  • Cabaletta Bio Q2 2026: $51M Net Loss, Going Concern Warning Despite $225M Cash

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$167.86M
Diluted EPS
-$2.10
Op. Cash Flow
-$131.08M
Free Cash Flow
-$132.31M
Operating Income
-$172.24M
Cash & Equivalents
$82.98M
Debt / Equity
0.00×
Shares Outstanding
100.48M sh
Source: 10-K · filed 2026-03-23 · accession 0001759138-26-000011

Short Interest & Short Volume

8.19 days to cover

FINRA reported short interest of 38,369,896 shares in CABA as of the October 30, 2026 settlement, a 2.3% decrease from the prior period — about 8.2 days to cover at its recent average daily volume. On November 20, 2026, 57.2% of CABA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)38,369,896 shares as of October 30, 2026
Change vs prior period▼ 2.3%
Days to cover8.19 at avg daily volume of 4,684,686
Daily short volume (FINRA facilities)57.2% of 1,856,659 shares on November 20, 2026
5-day average short volume63.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$0.9699 +3.61% today
52-week range · as of 2026-11-05 $0.9699 – $4.23
Market cap
$201.94M
Volume
3.7M (0.8× avg)
3-mo avg 4.8M
Live data · 2026-11-22 12:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CABA - Latest Insights

CABA
Nov 08, 2026, 10:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.34
Real-time Price: $0.9699 info
Change: -$0.3697 (-28%) info
Market Cap: $201.936M info
CABA
Nov 05, 2026, 7:34 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.48
Real-time Price: $0.9699 info
Change: -$0.5101 (-34%) info
Market Cap: $201.936M info
CABA
Nov 05, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.48
Real-time Price: $0.9699 info
Change: -$0.5101 (-34%) info
Market Cap: $201.936M info
CABA
Sep 14, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.77
Real-time Price: $0.9699 info
Change: -$1.80 (-65%) info
Market Cap: $201.936M info
CABA
Aug 13, 2026, 7:34 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.82
Real-time Price: $0.9699 info
Change: -$1.85 (-66%) info
Market Cap: $201.936M info
CABA
Aug 13, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.82
Real-time Price: $0.9699 info
Change: -$1.85 (-66%) info
Market Cap: $201.936M info
CABA
Aug 13, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.90
Real-time Price: $0.9699 info
Change: -$1.93 (-67%) info
Market Cap: $201.936M info
CABA
Jun 11, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.05
Real-time Price: $0.9699 info
Change: -$2.08 (-68%) info
Market Cap: $201.936M info
CABA
Jun 03, 2026, 7:03 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $3.83
Real-time Price: $0.9699 info
Change: -$2.86 (-75%) info
Market Cap: $201.936M info
CABA
Jun 03, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.70
Real-time Price: $0.9699 info
Change: -$2.73 (-74%) info
Market Cap: $201.936M info
CABA
Jun 01, 2026, 7:30 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $3.92
Real-time Price: $0.9699 info
Change: -$2.95 (-75%) info
Market Cap: $201.936M info
CABA
May 14, 2026, 7:08 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.71
Real-time Price: $0.9699 info
Change: -$2.74 (-74%) info
Market Cap: $201.936M info
CABA
May 14, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.71
Real-time Price: $0.9699 info
Change: -$2.74 (-74%) info
Market Cap: $201.936M info
CABA
May 14, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.71
Real-time Price: $0.9699 info
Change: -$2.74 (-74%) info
Market Cap: $201.936M info
CABA
May 04, 2026, 6:40 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.35
Real-time Price: $0.9699 info
Change: -$2.38 (-71%) info
Market Cap: $201.936M info
CABA
May 04, 2026, 6:37 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.15
Real-time Price: $0.9699 info
Change: -$2.18 (-69%) info
Market Cap: $201.936M info
CABA
May 04, 2026, 6:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.04
Real-time Price: $0.9699 info
Change: -$2.07 (-68%) info
Market Cap: $201.936M info
CABA
Apr 28, 2026, 7:31 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $2.90
Real-time Price: $0.9699 info
Change: -$1.93 (-67%) info
Market Cap: $201.936M info
CABA
Apr 20, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.44
Real-time Price: $0.9699 info
Change: -$2.47 (-72%) info
Market Cap: $201.936M info
CABA
Apr 17, 2026, 7:45 AM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $3.54
Real-time Price: $0.9699 info
Change: -$2.57 (-73%) info
Market Cap: $201.936M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets